AU642886B2 - T-lymphotropic retrovirus monoclonal antibodies - Google Patents
T-lymphotropic retrovirus monoclonal antibodies Download PDFInfo
- Publication number
- AU642886B2 AU642886B2 AU58355/90A AU5835590A AU642886B2 AU 642886 B2 AU642886 B2 AU 642886B2 AU 58355/90 A AU58355/90 A AU 58355/90A AU 5835590 A AU5835590 A AU 5835590A AU 642886 B2 AU642886 B2 AU 642886B2
- Authority
- AU
- Australia
- Prior art keywords
- hiv
- amino acid
- antigen
- antibody
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241001430294 unidentified retrovirus Species 0.000 title description 8
- 208000031886 HIV Infections Diseases 0.000 claims description 61
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 60
- 239000000427 antigen Substances 0.000 claims description 40
- 102000036639 antigens Human genes 0.000 claims description 40
- 108091007433 antigens Proteins 0.000 claims description 40
- 238000001514 detection method Methods 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 21
- 238000009007 Diagnostic Kit Methods 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- 230000008827 biological function Effects 0.000 claims description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 32
- 230000000052 comparative effect Effects 0.000 claims 3
- 101710205625 Capsid protein p24 Proteins 0.000 description 24
- 101710177166 Phosphoprotein Proteins 0.000 description 24
- 101710149279 Small delta antigen Proteins 0.000 description 24
- 102100031987 Transmembrane emp24 domain-containing protein 2 Human genes 0.000 description 24
- 238000002965 ELISA Methods 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 101710072850 Poxin Proteins 0.000 description 17
- 101710142282 Protein P26 Proteins 0.000 description 17
- 102100032106 Transmembrane emp24 domain-containing protein 3 Human genes 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000036436 anti-hiv Effects 0.000 description 8
- 239000006166 lysate Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 101710177291 Gag polyprotein Proteins 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102100023321 Ceruloplasmin Human genes 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002976 reverse transcriptase assay Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 102100029905 DNA polymerase epsilon subunit 3 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101710104359 F protein Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010015780 Viral Core Proteins Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 235000021538 Chard Nutrition 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35188289A | 1989-05-15 | 1989-05-15 | |
US351882 | 1989-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU5835590A AU5835590A (en) | 1990-12-18 |
AU642886B2 true AU642886B2 (en) | 1993-11-04 |
Family
ID=23382831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU58355/90A Ceased AU642886B2 (en) | 1989-05-15 | 1990-05-14 | T-lymphotropic retrovirus monoclonal antibodies |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0472659A4 (fr) |
JP (1) | JPH04505621A (fr) |
KR (1) | KR0168447B1 (fr) |
AU (1) | AU642886B2 (fr) |
CA (1) | CA2032509A1 (fr) |
FI (1) | FI915333A0 (fr) |
WO (1) | WO1990014358A1 (fr) |
ZA (1) | ZA903492B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK53291D0 (da) * | 1991-03-25 | 1991-03-25 | Carlbiotech Ltd As | Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser |
SE9101863D0 (sv) * | 1991-06-13 | 1991-06-13 | Replico Medical Ab | Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar |
JP4278174B2 (ja) * | 1994-10-20 | 2009-06-10 | アンスティテュ・パストゥール | Hiv−1のoグループ(またはサブグループ)レトロウイルス性抗原のヌクレオチド配列 |
FR2777285B1 (fr) * | 1998-04-10 | 2000-05-19 | Bio Merieux | Ligand peptidique presentant une affinite specifique vis-a-vis de la proteine p24 du retrovirus hiv-1 |
US6818392B2 (en) * | 2000-12-06 | 2004-11-16 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3076189A (en) * | 1988-02-25 | 1989-08-31 | Bio-Rad Laboratories, Inc. | Novel compositions and methods of use thereof |
AU5578590A (en) * | 1989-05-22 | 1990-11-22 | Akzo N.V. | Diagnostic test for detecting antibodies directed against antigens of one or more related viruses |
AU8976691A (en) * | 1990-12-14 | 1992-06-18 | Chiron Behring Gmbh & Co. | Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4755457A (en) * | 1985-02-05 | 1988-07-05 | Robert Guroff Marjorie | Method for detecting HTLV-III neutralizing antibodies in sera |
US4843011A (en) * | 1985-08-01 | 1989-06-27 | Akzo N.V. | Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production |
US4888290A (en) * | 1987-11-06 | 1989-12-19 | Coulter Corporation | Monoclonal antibody specific to HIV antigens |
US5173399A (en) * | 1988-06-10 | 1992-12-22 | Abbott Laboratories | Mouse monoclonal antibodies to hiv-1p24 and their use in diagnostic tests |
-
1990
- 1990-05-08 ZA ZA903492A patent/ZA903492B/xx unknown
- 1990-05-14 JP JP2508986A patent/JPH04505621A/ja active Pending
- 1990-05-14 CA CA002032509A patent/CA2032509A1/fr not_active Abandoned
- 1990-05-14 WO PCT/US1990/002874 patent/WO1990014358A1/fr not_active Application Discontinuation
- 1990-05-14 KR KR1019910700048A patent/KR0168447B1/ko not_active IP Right Cessation
- 1990-05-14 EP EP19900909217 patent/EP0472659A4/en not_active Ceased
- 1990-05-14 AU AU58355/90A patent/AU642886B2/en not_active Ceased
-
1991
- 1991-11-12 FI FI915333A patent/FI915333A0/fi unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3076189A (en) * | 1988-02-25 | 1989-08-31 | Bio-Rad Laboratories, Inc. | Novel compositions and methods of use thereof |
AU5578590A (en) * | 1989-05-22 | 1990-11-22 | Akzo N.V. | Diagnostic test for detecting antibodies directed against antigens of one or more related viruses |
AU8976691A (en) * | 1990-12-14 | 1992-06-18 | Chiron Behring Gmbh & Co. | Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0472659A4 (en) | 1992-04-08 |
EP0472659A1 (fr) | 1992-03-04 |
ZA903492B (en) | 1991-02-27 |
KR920701243A (ko) | 1992-08-11 |
AU5835590A (en) | 1990-12-18 |
FI915333A0 (fi) | 1991-11-12 |
CA2032509A1 (fr) | 1990-11-16 |
KR0168447B1 (ko) | 1999-01-15 |
WO1990014358A1 (fr) | 1990-11-29 |
JPH04505621A (ja) | 1992-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Palker et al. | Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. | |
Moore et al. | Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies | |
Moore et al. | A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B | |
Papsidero et al. | Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping | |
AU625970B2 (en) | Hiv-3 retrovirus and its use | |
Kayman et al. | Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains | |
JP2958346B2 (ja) | 抗HIV―2モノクローナル抗体およびそれを用いた抗HIV―2gp41抗体の検出方法 | |
IE61241B1 (en) | Monoclonal antibody specific to hiv antigens | |
US5256561A (en) | Monoclonal antibody to HIV-2 and uses thereof | |
WO1990006510A1 (fr) | Anticorps monoclonaux contre le lentivirus lymphotropique t | |
US5210181A (en) | T-lymphotropic retrovirus peptide | |
Hinkula et al. | Epitope mapping of the HIV-1 gag region with monoclonal antibodies | |
US5254457A (en) | Monoclonal antibodies and method for identifying different aids-related viruses | |
Avrameas et al. | Localisation of three epitopes of the env protein of feline immunodeficiency virus | |
AU642886B2 (en) | T-lymphotropic retrovirus monoclonal antibodies | |
Boucher et al. | Immune response and epitope mapping of a candidate HIV‐1 p17 vaccine HGP30 | |
VanCott et al. | Serotyping international HIV-1 isolates by V3 peptides and whole gp160 proteins using BIAcore | |
Walther et al. | Evaluation of HIV-1/HIV-2 immunoblots for detection of HIV-2 antibodies | |
San Hou et al. | Monoclonal antibodies against different epitopes of nonstructural protein ςNS of avian reovirus S1133 | |
Sibille et al. | Comparison of serological tests for the diagnosis of feline immunodeficiency virus infection of cats | |
Lombardi et al. | Detection of B epitopes on the p24 gag protein of feline immunodeficiency virus by monoclonal antibodies | |
Rimmelzwaan et al. | Gag-and env-specific serum antibodies in cats after natural and experimental infection with feline immunodeficiency virus | |
Norrby et al. | Immunochemistry of the dominating antigenic region Ala582 to Cys604 in the transmembranous protein of simian and human immunodeficiency virus. | |
US5624795A (en) | Isolation and characterization of a novel chimpanzee lentivirus, designated simian immunodeficiency virus isolate cpz-ant | |
Chiang et al. | Characterization of a monoclonal antibody specific to the Gag protein of porcine endogenous retrovirus and its application in detecting the virus infection |